公开(公告)号：US20250060373A1

公开(公告)日：2025-02-20

申请号：US18723433

申请日：2022-12-29

Applicant: The Progeria Research Foundation

Inventor： Leslie B. GORDON ,  Sarah HAMREN ,  Robert GOODSON

IPC: G01N33/68 ,  A61K31/4545 ,  G01N33/549

Abstract: Provided herein is a newly developed immunoassay that can detect progerin with high sensitivity, but which does not detect wildtype lamin A. Applications of the newly developed immunoassay in novel methods for diagnosing, prognosing, and treating progeria are also described.

公开(公告)号：US20250059188A1

公开(公告)日：2025-02-20

申请号：US18722104

申请日：2022-12-22

Applicant: Anaxis Pharma Pty Ltd

Inventor： Martin Brzozowski ,  Christophe Poitevin ,  Jean-Marc Daniel Garnier ,  Christopher Gardner ,  Guillaume Laurent Lessene ,  Peter Edward Czabotar ,  Carole Annie Schuster-Klein ,  Katherine Davies ,  Angus Cowan ,  Wilhelmus Johannes Antonius Kersten

IPC: C07D471/04 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  C07D487/04 ,  C07D491/08 ,  C07D519/00

Abstract: This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.

公开(公告)号：US20250059165A1

公开(公告)日：2025-02-20

申请号：US18789815

申请日：2024-07-31

Applicant: Boehringer Ingelheim International GmbH

Inventor： Jens WILLWACHER ,  Florian Paul Christian BINDER ,  Georg DAHMANN ,  Sandra Ruth HANDSCHUH ,  Sophia Astrid REINDL ,  James Young Soo YANG HAMILTON

IPC: C07D401/14 ,  A61K31/4545 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D498/04

Abstract: The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

公开(公告)号：US20250059164A1

公开(公告)日：2025-02-20

申请号：US18751286

申请日：2024-06-23

Applicant: Kymera Therapeutics, Inc.

Inventor： Xiaozhang ZHENG ,  Nello Mainolfi ,  Matthew M. Weiss

IPC: C07D401/14 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D519/00

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

公开(公告)号：US20250057930A1

公开(公告)日：2025-02-20

申请号：US18936652

申请日：2024-11-04

Applicant: The Children's Medical Center Corporation

Inventor： Roberto Chiarle ,  Rafael Blasco-Patino

IPC: A61K39/00 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/7084 ,  A61K39/395 ,  C12N9/12

Abstract: The invention features compositions and methods for treating anaplastic lymphoma kinase (ALK)-rearranged neoplasias including Non-Small Cell Lung Cancers (NSCLCs). The methods involve administering to a subject ALK peptides and/or polynucleotides encoding the ALK peptides, optionally in combination with an immune checkpoint inhibitor (ICI) and/or an ALK tyrosine kinase inhibitor (TKI).

公开(公告)号：US20250057838A1

公开(公告)日：2025-02-20

申请号：US18667468

申请日：2024-05-17

Applicant: Wylder Nation Foundation

Inventor： Maria Dolores LEDESMA ,  Adrian BARTOLL ,  Edward H. SCHUCHMAN

IPC: A61K31/501 ,  A61K9/00 ,  A61K31/16 ,  A61K31/164 ,  A61K31/232 ,  A61K31/325 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/573 ,  A61K35/28 ,  A61K45/06 ,  A61P1/00 ,  A61P25/28 ,  C12N9/16

Abstract: The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.

公开(公告)号：US20250057828A1

公开(公告)日：2025-02-20

申请号：US18722233

申请日：2022-12-20

Applicant: BAYER AKTIENGESELLSCHAFT

Inventor： Martina DELBECK ,  Michael HAHN

IPC: A61K31/4545 ,  A61K31/222 ,  A61K45/06

Abstract: The present invention relates to a combination of a muscarinic receptor antagonist and α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

公开(公告)号：US20250051332A1

公开(公告)日：2025-02-13

申请号：US18922525

申请日：2024-10-22

Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS ,  PURDUE RESEARCH FOUNDATION

Inventor： ANDREW RILEY ,  RICHARD VAN RIJN ,  ANNA GUTRIDGE ,  SIMONE CREED

IPC: C07D471/20 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/5377 ,  A61P25/04

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that can bind to one or more opioid receptors. In one aspect, the compounds described herein can bind to the kappa opioid receptor (κOR) and behave as an opioid receptor agonist. The ability of the compounds to bind to opioid receptors make them effective in the treatment or prevention of pain such as chronic pain.

公开(公告)号：US20250051305A1

公开(公告)日：2025-02-13

申请号：US18558337

申请日：2023-07-28

Applicant: Sumitomo Pharma Co., Ltd.

Inventor： Hitoshi WATANABE ,  Shuya YAMADA ,  Katsushi KITAHARA ,  Mariko KOBAYASHI

IPC: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/553 ,  C07D405/14 ,  C07D413/14 ,  C07D491/04

Abstract: The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

公开(公告)号：US20250042896A1

公开(公告)日：2025-02-06

申请号：US18705948

申请日：2022-10-28

Applicant: HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.

Inventor： Wansun MAI ,  Xiaowu LIU ,  Wenqiang SHI ,  Zhixiong DENG ,  Wei ZHU ,  Zhengtao LI ,  Hao ZOU

IPC: C07D471/04 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/519 ,  C07D405/10 ,  C07D405/14 ,  C07D491/052 ,  C07D513/04

Abstract: The present application describes a polycyclic compound represented by general formula (I) as a Cbl-b inhibitor, or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound of general formula (I) or the stereoisomer or pharmaceutically acceptable salt thereof, and a use of the compound of general formula (I) or the stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the prevention or treatment of diseases or conditions mediated by Cbl-b.